康宁杰瑞“涅槃新生”?

医曜
18 Jun

本文系基于公开资料撰写,仅作为信息交流之用,不构成任何投资建议。创新药从来不缺逆风翻盘的故事,曾经的“双抗之星”康宁杰瑞似乎正在上演这样的剧本。我们将时间拉回到2024年5月,继鳞状非小细胞肺癌失利后,康宁杰瑞核心双抗KN046在胰腺癌的III期临床中再度受挫。一次次的失利,让失望的投资者们相继离开,康宁杰瑞股价一度跌至2港元/股,市值仅剩25亿港元。为了破局,康宁杰瑞决心将重点转至HER2双抗...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10